FORMULATION ARTICLES
-
The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology
Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.
-
Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit
Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.
-
Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage
Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.
-
Targeted Delivery – A Holy Grail For CRISPR Gene Editing
Precise CRISPR delivery remains the bottleneck to safer, more potent gene editing. Advances in LNP design, targeting strategies, and extrahepatic delivery are redefining what’s possible in vivo.
-
The Hidden Physics Of RNA-LNPs: Tuning RNA Encapsulation For Potency And Safety
Why LNPs that look identical behave differently in cells. This piece reveals how mixing physics and payload uniformity shape RNA potency, safety, dosing, and manufacturability—beyond size alone.
-
Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success
As RNA pipelines mature, delivery success demands shared benchmarks. This article proposes standardized, stage-specific metrics to compare platforms, guide optimization, and strengthen regulatory confidence.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Precision In Nanoparticle Processing And Monodispersed Lipid Nanoparticles For Advanced Therapeutics
Precision in nanoparticle processing is key for drug delivery and vaccines. Learn how monodispersed formulations enhance reproducibility and stability for next-generation therapeutics, like RNA-LNPs.
-
Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced bio-therapeutics such as mRNA vaccines.
-
As pharma companies aim to overcome development obstacles, it is important to incorporate GMP expertise alongside novel technologies that can enhance the properties of APIs and dosage forms.
-
Explore this proprietary ionizable lipid library which has shown promising potency towards various applications involving cell therapy, protein replacement therapy and RNA-based Vaccines.
-
Explore how an optimized solid‑support design enables higher synthesis scales, steadier pressures, and lower solvent use while preserving yield and purity across diverse oligonucleotide lengths.
-
We aim to highlight that commercially available LNP reagent mix, GenVoy-ILM, is an accessible and easy-to-use LNP formulation that allows for rapid preclinical development of RNA vaccines.
-
The path to regulatory approval for LNPs demands carefully considered strategies. By adopting proactive and strategic approaches, developers can overcome regulatory hurdles on the path to approval.